Shares of Fate Therapeutics Inc. (NASDAQ:FATE) traded up 4.7% during mid-day trading on Monday . The company traded as high as $2.70 and last traded at $2.68, with a volume of 122,649 shares. The stock had previously closed at $2.56.

A number of analysts have issued reports on the company. BMO Capital Markets set a $4.00 price target on Fate Therapeutics and gave the stock a “buy” rating in a report on Monday, August 8th. HC Wainwright reiterated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, August 9th. Zacks Investment Research upgraded Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Thursday. Leerink Swann reiterated an “outperform” rating and set a $4.00 target price on shares of Fate Therapeutics in a research report on Tuesday, June 21st. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, May 10th. Eight analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $6.29.

The company’s market cap is $78.88 million. The stock’s 50-day moving average is $1.91 and its 200 day moving average is $1.85.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. The company earned $1.03 million during the quarter, compared to analyst estimates of $1.02 million. On average, equities analysts expect that Fate Therapeutics Inc. will post ($1.17) earnings per share for the current fiscal year.

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.